Appetite Stimulants for Treatment of Protein Energy Wasting of Chronic Kidney Disease.

Nutritional and metabolic abnormalities, or protein energy wasting, is a common complication of chronic kidney disease, leading to significant morbidity and mortality. The cause of these abnormalities is multifactorial, and therefore, difficult to treat. The International Society of Renal Nutrition and Metabolism suggests appetite stimulants, including megestrol, dronabinol, mirtazapine, and cyproheptadine, as adjunctive treatment options in addition to parenteral or oral nutritional supplementation.

First Responder knowledge, perception and confidence in administering naloxone: Impact of a pharmacist-provided educational program in rural Mississippi.

Objective: In July 2017, Mississippi passed House Bill 996, which permitted first responders to carry naloxone and required training before administration. There is no standard training offered in Mississippi for first responders. The purpose was to evaluate the change in first responder knowledge, perceptions, and confidence in administering naloxone after pharmacist training.

Medication pitfalls in the CKD clinic: case presentations.

The kidney plays a major role in pharmacokinetics and pharmacodynamics of drugs; therefore, medication errors can result from failure to properly adjust medications in patients with CKD. It is the responsibility of all health-care providers to work collectively when reviewing medications, initiating new medications, and adjusting doses of current medications. Awareness of appropriate dosing recommendations can significantly decrease medication error-associated morbidity, mortality, and cost.

Medication dosing in patients with chronic kidney disease.

Appropriate dosage adjustments for patients with chronic kidney disease (CKD) are critical for patient safety. This article reviews adjustments for common antidiabetic, antibiotic, analgesic, and antithrombotic medications, as well as important patient teaching information for over-the-counter (OTC) medications.

Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease.

Purpose: The evidence evaluating the efficacy of i.v. versus oral iron for the treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease (CKD) is reviewed.

Medication considerations for patients with chronic kidney disease who are not yet on dialysis.

Because the kidney plays a large role in the absorption, distribution, metabolism, and elimination of drugs, significant medication-related problems can result from failure to properly adjust medications in patients with chronic kidney disease. It is the responsibility of all healthcare providers to be aware of necessary dose adjustments when reviewing medications, assessing drug therapy, changing drug therapy, or prescribing new medications.